| Literature DB >> 30018077 |
Sophie Lepropre1, Shakeel Kautbally1, Marie Octave1, Audrey Ginion1, Marie-Blanche Onselaer1,2, Gregory R Steinberg3, Bruce E Kemp4,5, Alexandre Hego6, Odile Wéra6, Sanne Brouns7, Frauke Swieringa7, Martin Giera8, Victor M Darley-Usmar9, Jérôme Ambroise10, Bruno Guigas11,12, Johan Heemskerk7, Luc Bertrand1, Cécile Oury6, Christophe Beauloye1,13, Sandrine Horman1.
Abstract
AMP-activated protein kinase (AMPK) α1 is activated in platelets on thrombin or collagen stimulation, and as a consequence, phosphorylates and inhibits acetyl-CoA carboxylase (ACC). Because ACC is crucial for the synthesis of fatty acids, which are essential for platelet activation, we hypothesized that this enzyme plays a central regulatory role in platelet function. To investigate this, we used a double knock-in (DKI) mouse model in which the AMPK phosphorylation sites Ser79 on ACC1 and Ser212 on ACC2 were mutated to prevent AMPK signaling to ACC. Suppression of ACC phosphorylation promoted injury-induced arterial thrombosis in vivo and enhanced thrombus growth ex vivo on collagen-coated surfaces under flow. After collagen stimulation, loss of AMPK-ACC signaling was associated with amplified thromboxane generation and dense granule secretion. ACC DKI platelets had increased arachidonic acid-containing phosphatidylethanolamine plasmalogen lipids. In conclusion, AMPK-ACC signaling is coupled to the control of thrombosis by specifically modulating thromboxane and granule release in response to collagen. It appears to achieve this by increasing platelet phospholipid content required for the generation of arachidonic acid, a key mediator of platelet activation.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30018077 PMCID: PMC6238154 DOI: 10.1182/blood-2018-02-831503
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113